The introduction of CFTR modulators—currently, the four marketed are ivacaftor, lumacaftor, tezacaftor, and elexacaftor—in the clinic has revolutionized the life of people with CF (pwCF) by improving lung function and reducing exacerbations of the disease in patients with CF [1]. The gene discussed is CFTR; the disease is cystic fibrosis.